HOME >> BIOLOGY >> NEWS
AVANT to develop an oral anthrax and plague vaccine for U.S. Department of Defense

This release has been updated as of Monday January 21st.

NEEDHAM, MA (January 22, 2003): AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced it has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. Under the agreement, AVANT may receive in excess of $8 million over a two-year period, covering vaccine development through preclinical testing. AVANT executed the subcontract with DynPort Vaccine Company LLC ("DVC"), the prime contractor for the Defense Department's Joint Vaccine Acquisition Program (JVAP). Headquartered in Fort Detrick, MD, JVAP is the lead Defense Department organization for the development and purchase of vaccines for the U.S. military.

"This contract represents one of the first awards from a major U.S. Department of Defense (DoD) initiative to apply modern biotechnological innovations to the development of vaccines that can offer rapid, effective protection from multiple biological agents," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "Current vaccines against bacterial bioweapons like anthrax (Bacillus anthracis) and plague (Yersinia pestis) require a protracted dosing regimen or provide only limited protection, and each vaccine protects against only a single agent. The Defense Department is looking for new, improved generation vaccines that are effective, single-dose, and can protect against multiple agents. The choice of AVANT to conduct this development program is an important recognition of the strength of AVANT's vaccine and vector technologies for accomplishing these aims."

"This contract is very important to AVANT since it provides non-dilutive funding to the company and it means that AVANT now has over two years of cash and cash equivalents on hand," Dr. Ryan concluded.

Senator Edward M. Kennedy (D-MA), Ranking Dem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-281-2413
Kureczka/Martin Associates
22-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Clinical results with AVANT rotavirus vaccine demonstrate nearly 90% protection in young children
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Wisconsin scientists develop quick botox test
5. Bronfenbrenner book sums up human development
6. Researchers develop fast track way to discover how cells are regulated
7. DuPont developing new protective suits for military, first responders
8. OutFoxed! New research may redefine late-stage cardiac development
9. Computer scientists at UH developing nurturing computers
10. Disease diagnosis, drug development focus of UH profs biochip research
11. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies

Post Your Comments:
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
(Date:2/24/2015)... 2015 This report analyzes the worldwide markets for Face ... Biometrics, and Voice Biometrics. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific , ... , and Latin America . Annual estimates and ... seven-year historic analysis is provided for these markets. Market data and ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
(Date:3/30/2015)... IRVINE, Calif. , March 30, 2015 /PRNewswire/ ... that its subsidiary corporation, NuGene BioPharma, Inc. has ... board. Dr. Guan is an internationally ... After finishing his college education at Peking University, ... his Ph.D. degree from the University of North ...
(Date:3/30/2015)... , March 30, 2015    Intrexon Corporation ... synthetic biology, and Merck Serono, the biopharmaceutical business ... , today announced an exclusive strategic collaboration and ... Receptor T-cell (CAR-T) cancer therapies. This collaboration advances ... therapies that modulate the immune system,s natural ability ...
(Date:3/30/2015)... , March 30, 2015 ... auf    Richmond Pharmacology ist das erste ... Amyloidose-Zentrum am Royal Free Hospital in ... zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten ... von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen ...
(Date:3/29/2015)... March 29, 2015 As a symbol ... required by our pharmaceutical manufacturing clients, Whitehouse Laboratories is ... of the Berkenstock Race Team for the 2015 race ... only speed, but a strong sense of precision and ... lead to success in the quality control testing laboratory. ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
Cached News: